Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011029842 - SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER

Publication Number WO/2011/029842
Publication Date 17.03.2011
International Application No. PCT/EP2010/063169
International Filing Date 08.09.2010
IPC
C07D 471/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07C 311/20 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
311Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
20having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • NOVARTIS AG [CH]/[CH] (AllExceptUS)
  • MILLER-MOSLIN, Karen [US]/[US] (UsOnly)
  • TOURE, Bakary-Barry [CA]/[US] (UsOnly)
  • VISSER, Michael Scott [US]/[US] (UsOnly)
  • YUSUFF, Naeem [US]/[US] (UsOnly)
Inventors
  • MILLER-MOSLIN, Karen
  • TOURE, Bakary-Barry
  • VISSER, Michael Scott
  • YUSUFF, Naeem
Agents
  • STRANG, Andrea
Priority Data
61/241,25110.09.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER
(FR) SULFAMIDES UTILISÉS COMME INHIBITEURS DES PROTÉINES DE LA FAMILLE DE BCL-2 DANS LE TRAITEMENT DU CANCER
Abstract
(EN)
The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of Formula (I) or pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Bcl-2 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula (I) and pharmaceutically acceptable salts thereof.
(FR)
Cette invention concerne un nouveau composé et des méthodes de traitement d'une maladie ou d'une affection en inhibant les protéines de la famille Bcl-2, en particulier les composés de formule (I) ou leurs sels pharmaceutiquement acceptables, ainsi que des méthodes de traitement d'une maladie, d'une affection ou d'un syndrome associé(e) avec l'inhibition de Bcl-2, en particulier les maladies hyperprolifératives. L'invention concerne également des compositions pharmaceutiques comprenant les composés de formule 1 et leurs sels pharmaceutiquement acceptables.
Latest bibliographic data on file with the International Bureau